Accéder au contenu
Merck
Toutes les photos(1)

Documents

A-903

Supelco

Alprazolam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C17H13ClN4
Numéro CAS:
28981-97-7
Poids moléculaire :
308.76
Numéro CE :
200-659-6
Numéro MDL:
MFCD00078881
Code UNSPSC :
41116107
ID de substance PubChem :
329771027
Nomenclature NACRES :
NA.24

Qualité

certified reference material

Niveau de qualité

300

Forme

liquid

Caractéristiques

SNAP-N-SPIKE®, SNAP-N-SHOOT®

Conditionnement

ampule of 1 mL

Fabricant/nom de marque

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

Concentration

1.0 mg/mL in methanol

Technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Application(s)

clinical testing

Format

single component solution

Température de stockage

−20°C

Chaîne SMILES 

Cc1nnc2CN=C(c3ccccc3)c4cc(Cl)ccc4-n12

InChI

1S/C17H13ClN4/c1-11-20-21-16-10-19-17(12-5-3-2-4-6-12)14-9-13(18)7-8-15(14)22(11)16/h2-9H,10H2,1H3

Clé InChI

VREFGVBLTWBCJP-UHFFFAOYSA-N

Informations sur le gène

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Alprazolam is a benzodiazepine drug used for the medical treatment of anxiety and panic disorders, including generalized or social anxiety disorder. This certified reference standard is suitable for use in a wide variety of LC/MS or GC/MS testing applications from forensic analysis and clinical toxicology to urine drug testing and pain prescription monitoring. Alprazolam is sold under the trade name Xanax®.

Application


  • Alprazolam Solid Lipid Nanoparticles for Sustained Release: This study explores the development of Compritol-based Alprazolam solid lipid nanoparticles, demonstrating a novel approach for sustained release formulations in benzodiazepine biochemistry. The technique is critical for improving the pharmacokinetics of anxiolytic compounds, ensuring controlled release and enhanced bioavailability (Rao et al., 2022).

  • Extraction of Alprazolam in Biological Samples: Application of dispersive solid-phase extraction using nanographene oxide grafted with α-pyridylamine for alprazolam, which is significant for forensic and clinical toxicology. This method enhances the precision of benzodiazepine detection in complex biological matrices, pivotal for neuropharmacological studies (Parsayi Arvand et al., 2023).

  • Raman Spectroscopy in Drug Abuse Analysis: Utilization of portable Raman spectroscopy for the detection of drugs of abuse, including Alprazolam. This research underscores the importance of Alprazolam research solutions in developing rapid and non-destructive testing methods, contributing to advancements in forensic science (Santos et al., 2022).

Informations légales

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Xanax is a registered trademark of Pharmacia & Upjohn Company

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

A-902

Alprazolam-d5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-904

alpha-Hydroxyalprazolam-d5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-907

alpha-Hydroxyalprazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-908

alpha-Hydroxyalprazolam-d5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

A-910

Alprazolam-d5 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

B-033

Benzodiazepine Multi-component Mixture-8 solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

IMF-020S

iMethod Test Kit for Benzodiazepines with Synthetic Urine, kit of 23 × 1.0 mL ampules, certified reference material, Cerilliant®

H-142

4-Hydroxyalprazolam solution, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

H-143

4-Hydroxyalprazolam-D5 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

F-095

Flualprazolam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

F-096

Flualprazolam-D4 solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

B-108

Bromazolam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

Pictogrammes

FlameSkull and crossbonesHealth hazard
GHS02,GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organes cibles

Eyes,Central nervous system

Code de la classe de stockage

3 - Flammable liquids

Classe de danger pour l'eau (WGK)

WGK 2

Point d'éclair (°F)

49.5 °F - closed cup

Point d'éclair (°C)

9.7 °C - closed cup

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

J M Jonas et al.
The Journal of clinical psychiatry, 54 Suppl, 25-45 (1993-10-01)
A review of the worldwide published literature was conducted to assess the efficacy and safety of alprazolam for the treatment of anxiety disorders, panic disorder, and depression in comparison with those of other active drugs (including other benzodiazepines and antidepressant
J O Cole et al.
The Journal of clinical psychiatry, 54 Suppl, 49-61 (1993-10-01)
A review of the published case reports of adverse behavioral episodes or unexpected psychopathology in patients taking benzodiazepines was undertaken in an attempt to determine if these adverse or unexpected events are more likely to occur with alprazolam when compared
Dean T Acheson et al.
Human psychopharmacology, 27(4), 419-427 (2012-07-12)
Heightened anticipation of future events has been characterized as a feature of certain anxiety disorders. In functional magnetic resonance imaging studies, anticipation of fearful/threatening images has been shown to robustly activate the insular cortex and amygdala in healthy subjects, in
E M Sellers et al.
The Journal of clinical psychiatry, 54 Suppl, 64-75 (1993-10-01)
The incidence of nonmedical use of alprazolam is very low relative to its widespread legitimate medical use; in fact, given the millions of patients who have received this medication, the incidence is remarkably small. In particular, among patients with anxiety
Gregor Leicht et al.
Biological psychiatry, 73(4), 337-344 (2012-10-13)
Benzodiazepines modulate γ-aminobutyric acid type A (GABA(A)) receptors throughout the brain. However, it is not fully understood which brain regions within anxiety-related brain circuits are really responsible for their anxiolytic effects and how these regions interact. We investigated whether the
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique